| Boosted |
|---|
|
No
|
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Nevirapine SQV 638 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Decreased saquinavir effects |
Not studied |
600 mg (hard gel caps) TID | Saquinavir AUC decreased 24%; Cmax decreased 28% |
Use alternative agents |
| Efavirenz Saquinavir 469 | Red: Avoid combination | Minimal data to guide interaction, weigh risks and benefits of using this combination | Potential loss of antiviral efficacy |
1200 mg every 8 hours for 10 days | AUC decreased 62%, Cmin decreased 56%, Cmax decreased %50 |
Use alternative agents |
|
| Efavirenz Saquinavir 468 | Red: Avoid combination | Minimal data to guide interaction, weigh risks and benefits of using this combination | Potential loss of antiviral efficacy |
1200 mg every 8 hours for 10 days | AUC decreased 62%, Cmin decreased 56%, Cmax decreased %50 |
Use alternative agents |
